Hospital
Duke University Health System, INC.
Duke University Health System, INC. was paid $44.35M by Medicaid between Jan 2018 and Dec 2024, across 363 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 14% of everything it billed.
33Billing provider infoDUKE UNIVERSITY HEALTH SYSTEM, INC.
DURHAM, NC 27710
DURHAM, NC 27710
33aNPI1992703540assigned 07/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.35M
24GClaims1,040,578
24DCodes billed363
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#10 of 92
Median peer was paid$11.47M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, JOHN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 158,081 | $5.34M | |
| 2019 | 151,081 | $5.38M | |
| 2020 | 107,749 | $3.59M | |
| 2021 | 176,551 | $7.42M | |
| 2022 | 161,305 | $7.55M | |
| 2023 | 142,833 | $7.03M | |
| 2024incomplete | 142,978 | $8.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14% | 189,163 | 172,280 | $6.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 16,820 | 14,905 | $6.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 23,104 | 21,842 | $4.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.8% | 10,206 | 9,498 | $3.02M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 19,441 | 17,847 | $1.73M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 31,190 | 28,532 | $1.34M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 20,349 | 8,048 | $1.31M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.5% | 15,210 | 5,423 | $1.12M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.8% | 608 | 529 | $815K |
| 59025 | Fetal non-stress test | 1.8% | 14,150 | 8,275 | $812K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.5% | 6,685 | 5,791 | $668K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.4% | 12,969 | 11,590 | $642K |
351 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 19,915 | $590K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.3% | 5,728 | $574K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,487 | $554K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 3,110 | $540K |
| 80053 | Comprehensive metabolic panel | 1.1% | 47,846 | $476K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 60,097 | $464K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.0% | 1,049 | $460K |
| 92567 | <1% | 2,524 | $405K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,937 | $382K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,410 | $365K |
| J3490 | Unclassified drugs | <1% | 36,952 | $336K |
| 36415 | Collection of venous blood by venipuncture | <1% | 95,059 | $316K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,739 | $305K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,738 | $305K |
| 76801 | <1% | 3,210 | $274K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 650 | $268K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 756 | $258K |
| 93505 | <1% | 338 | $253K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,358 | $249K |
| 76770 | <1% | 1,977 | $238K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 68 | $232K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,615 | $198K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 420 | $197K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,206 | $177K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,274 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,888 | $159K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,413 | $158K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 324 | $155K |
| 95811 | <1% | 406 | $153K | |
| 93320 | <1% | 1,053 | $146K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,739 | $141K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,746 | $135K |
| 72082 | <1% | 1,964 | $132K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,838 | $131K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,515 | $131K |
| 95700 | <1% | 286 | $128K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 19 | $128K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,930 | $124K |
| 85027 | <1% | 20,668 | $121K | |
| 76820 | <1% | 1,054 | $110K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,099 | $109K |
| 93325 | <1% | 1,280 | $108K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,720 | $106K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,112 | $105K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 322 | $101K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,606 | $100K |
| 92526 | <1% | 1,169 | $98K | |
| 87631 | <1% | 1,099 | $91K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 768 | $91K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 185 | $90K |
| 86780 | <1% | 5,306 | $89K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,221 | $88K |
| 94010 | <1% | 1,064 | $84K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 117 | $83K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,705 | $80K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,153 | $75K |
| 94799 | <1% | 790 | $71K | |
| 87799 | <1% | 2,377 | $68K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 216 | $68K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,405 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,675 | $64K |
| 64642 | <1% | 466 | $63K | |
| 83735 | <1% | 12,536 | $63K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,616 | $62K |
| 87497 | <1% | 2,536 | $62K | |
| 84439 | <1% | 6,170 | $61K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 825 | $59K |
| 80197 | <1% | 5,454 | $59K | |
| 86850 | <1% | 5,797 | $56K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 818 | $53K |
| 88307 | <1% | 471 | $51K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 451 | $51K |
| 94770 | <1% | 1,079 | $51K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,380 | $49K |
| 86828 | <1% | 1,904 | $48K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,126 | $46K |
| 0002A | <1% | 775 | $46K | |
| 97162 | <1% | 908 | $46K | |
| 87634 | <1% | 473 | $46K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,038 | $43K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 888 | $43K |
| 82728 | <1% | 3,358 | $42K | |
| 54161 | <1% | 41 | $42K | |
| 0001A | <1% | 790 | $42K | |
| 80061 | Lipid panel | <1% | 3,066 | $41K |
| 87081 | <1% | 5,765 | $41K | |
| 96415 | <1% | 434 | $40K | |
| 86832 | <1% | 543 | $39K | |
| 85046 | <1% | 6,197 | $36K | |
| Q3014 | Telehealth originating site facility fee | <1% | 3,515 | $35K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 49 | $34K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 405 | $33K |
| 96376 | <1% | 687 | $33K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 231 | $33K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 264 | $33K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 41 | $33K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,140 | $32K |
| 82977 | <1% | 3,880 | $32K | |
| 82784 | <1% | 1,912 | $30K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 618 | $29K |
| D2330 | <1% | 69 | $28K | |
| 86803 | <1% | 1,592 | $28K | |
| 81025 | <1% | 3,623 | $27K | |
| 95953 | <1% | 50 | $26K | |
| 86762 | <1% | 1,429 | $26K | |
| 85610 | <1% | 7,314 | $26K | |
| 86003 | <1% | 370 | $25K | |
| 76813 | <1% | 720 | $25K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,096 | $25K |
| 64643 | <1% | 285 | $25K | |
| 83020 | <1% | 1,752 | $24K | |
| 92555 | <1% | 141 | $24K | |
| 87340 | <1% | 2,068 | $23K | |
| 82570 | <1% | 5,011 | $23K | |
| 95816 | <1% | 89 | $22K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 71 | $22K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,166 | $22K |
| 95711 | <1% | 35 | $21K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 239 | $21K |
| 81001 | <1% | 7,083 | $21K | |
| 36430 | <1% | 87 | $20K | |
| 76377 | <1% | 226 | $20K | |
| 86787 | <1% | 1,215 | $20K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 42 | $19K |
| 86833 | <1% | 282 | $19K | |
| 36512 | <1% | 52 | $18K | |
| 81003 | <1% | 3,327 | $17K | |
| C1769 | Guide wire | <1% | 727 | $16K |
| 84156 | <1% | 4,587 | $15K | |
| 97597 | <1% | 320 | $15K | |
| 84100 | <1% | 4,970 | $15K | |
| 80069 | <1% | 2,389 | $15K | |
| 93308 | <1% | 81 | $15K | |
| 86900 | <1% | 5,802 | $15K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 70 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 872 | $15K |
| 86901 | <1% | 5,800 | $14K | |
| 97803 | <1% | 1,322 | $14K | |
| 97602 | <1% | 613 | $13K | |
| 90686 | <1% | 2,722 | $13K | |
| 94150 | <1% | 370 | $13K | |
| D1120 | Dental cleaning, child | <1% | 228 | $13K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 121 | $13K |
| 92523 | <1% | 121 | $12K | |
| 95874 | <1% | 496 | $12K | |
| 94761 | <1% | 376 | $12K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,747 | $12K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 432 | $12K |
| D1351 | Sealant - per tooth | <1% | 103 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,715 | $12K |
| 82248 | <1% | 2,054 | $11K | |
| 83615 | <1% | 2,766 | $11K | |
| 72170 | <1% | 166 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,318 | $10K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 15 | $10K |
| 76932 | <1% | 81 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 105 | $9K |
| 29581 | <1% | 394 | $9K | |
| 83655 | <1% | 829 | $9K | |
| 0071A | <1% | 135 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 96 | $9K |
| 83550 | <1% | 991 | $9K | |
| 83540 | <1% | 1,248 | $9K | |
| 0072A | <1% | 129 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 99 | $8K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 195 | $8K |
| 83880 | <1% | 225 | $8K | |
| 94760 | <1% | 1,473 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,884 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,828 | $7K |
| 85730 | <1% | 2,359 | $7K | |
| 0124A | <1% | 153 | $7K | |
| 0004A | <1% | 143 | $7K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 90 | $7K |
| 86140 | <1% | 1,513 | $7K | |
| 93321 | <1% | 84 | $7K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 17 | $6K |
| 86160 | <1% | 335 | $6K | |
| 87210 | <1% | 1,261 | $6K | |
| 36592 | <1% | 332 | $6K | |
| 82550 | <1% | 1,388 | $6K | |
| 80076 | <1% | 621 | $6K | |
| 83520 | <1% | 373 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,492 | $5K |
| 87536 | <1% | 217 | $5K | |
| 82950 | <1% | 788 | $5K | |
| 86902 | <1% | 183 | $5K | |
| 82565 | <1% | 1,381 | $5K | |
| 85652 | <1% | 1,510 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,283 | $4K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 62 | $4K |
| 83970 | <1% | 169 | $4K | |
| 84702 | <1% | 418 | $4K | |
| 97163 | <1% | 70 | $4K | |
| 97167 | <1% | 42 | $4K | |
| 82105 | <1% | 161 | $4K | |
| 84450 | <1% | 1,012 | $4K | |
| 82610 | <1% | 247 | $4K | |
| 84460 | <1% | 1,179 | $4K | |
| 76376 | <1% | 790 | $4K | |
| 86225 | <1% | 253 | $3K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 61 | $3K |
| 86334 | <1% | 172 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 271 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 352 | $3K |
| 64615 | <1% | 28 | $3K | |
| 83690 | <1% | 366 | $3K | |
| 86923 | <1% | 60 | $3K | |
| 36591 | <1% | 457 | $3K | |
| 87632 | <1% | 15 | $3K | |
| 86141 | <1% | 170 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13 | $3K |
| 0054A | <1% | 63 | $3K | |
| 92552 | <1% | 16 | $3K | |
| 58300 | <1% | 43 | $2K | |
| 86922 | <1% | 24 | $2K | |
| 93750 | <1% | 59 | $2K | |
| 0012A | <1% | 39 | $2K | |
| 93356 | <1% | 421 | $2K | |
| 84165 | <1% | 232 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 251 | $2K |
| 83525 | <1% | 159 | $2K | |
| 97750 | <1% | 39 | $2K | |
| 93225 | <1% | 25 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $2K |
| 81370 | <1% | 28 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,834 | $2K |
| 77073 | <1% | 37 | $2K | |
| 71271 | <1% | 13 | $2K | |
| 82043 | <1% | 335 | $2K | |
| 96367 | <1% | 21 | $2K | |
| 84484 | <1% | 188 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 221 | $2K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 12 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 206 | $1K |
| 84446 | <1% | 75 | $1K | |
| 92557 | <1% | 14 | $1K | |
| 73100 | <1% | 33 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 178 | $1K |
| 97166 | <1% | 32 | $1K | |
| 0011A | <1% | 28 | $1K | |
| 81376 | <1% | 28 | $1K | |
| 90461 | <1% | 88 | $1K | |
| 86364 | <1% | 92 | $1K | |
| 82785 | <1% | 86 | $1K | |
| 0064A | <1% | 13 | $1K | |
| 96401 | <1% | 19 | $1K | |
| 76937 | <1% | 14 | $995.61 | |
| 84590 | <1% | 62 | $979.82 | |
| 86481 | <1% | 16 | $977.76 | |
| 94618 | <1% | 13 | $977.20 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 96 | $972.44 |
| 84550 | <1% | 166 | $924.36 | |
| 93296 | <1% | 57 | $909.11 | |
| 90656 | <1% | 112 | $887.81 | |
| 81329 | <1% | 17 | $863.66 | |
| 83718 | <1% | 77 | $791.52 | |
| 0031A | <1% | 12 | $780.00 | |
| 91322 | <1% | 12 | $760.19 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 53 | $756.84 |
| 83883 | <1% | 64 | $747.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,237 | $719.97 |
| 82378 | <1% | 39 | $682.15 | |
| 83721 | <1% | 70 | $673.80 | |
| 84403 | <1% | 16 | $649.00 | |
| 82247 | <1% | 181 | $646.88 | |
| 86665 | <1% | 60 | $642.24 | |
| 82948 | <1% | 271 | $626.36 | |
| 86706 | <1% | 58 | $617.10 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 44 | $597.55 |
| 86645 | <1% | 42 | $593.36 | |
| 85660 | <1% | 104 | $584.05 | |
| 82607 | <1% | 55 | $566.91 | |
| 80180 | <1% | 29 | $566.73 | |
| 97161 | <1% | 16 | $566.16 | |
| 82465 | <1% | 100 | $540.36 | |
| 82553 | <1% | 94 | $539.16 | |
| 97802 | <1% | 29 | $538.13 | |
| 58100 | <1% | 13 | $532.33 | |
| 80164 | <1% | 26 | $509.55 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 12 | $491.49 |
| 87077 | <1% | 37 | $484.97 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 35 | $469.20 |
| 82670 | <1% | 13 | $468.27 | |
| 86255 | <1% | 29 | $457.04 | |
| 84075 | <1% | 187 | $455.28 | |
| 85018 | <1% | 131 | $452.75 | |
| 82787 | <1% | 17 | $451.07 | |
| 86664 | <1% | 31 | $443.81 | |
| 84480 | <1% | 27 | $441.75 | |
| 84478 | <1% | 212 | $437.66 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 36 | $432.12 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 368 | $430.38 |
| 83051 | <1% | 85 | $428.54 | |
| 36416 | <1% | 1,923 | $427.95 | |
| 86644 | <1% | 31 | $413.20 | |
| 94375 | <1% | 150 | $410.71 | |
| 54150 | <1% | 13 | $402.48 | |
| 86038 | <1% | 25 | $395.25 | |
| 86663 | <1% | 31 | $377.45 | |
| 86735 | <1% | 29 | $375.05 | |
| 86765 | <1% | 29 | $370.19 | |
| 82330 | <1% | 32 | $368.14 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12 | $366.72 |
| 87205 | <1% | 98 | $351.03 | |
| 82805 | <1% | 12 | $340.54 | |
| 86708 | <1% | 28 | $339.87 | |
| 83605 | <1% | 42 | $334.68 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $324.64 |
| 94664 | <1% | 13 | $320.76 | |
| 91300 | <1% | 2,074 | $297.71 | |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | <1% | 45 | $270.15 |
| 82657 | <1% | 12 | $270.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 76 | $254.07 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 289 | $252.05 |
| 83521 | <1% | 148 | $242.33 | |
| 90694 | <1% | 13 | $238.00 | |
| 82232 | <1% | 13 | $236.16 | |
| 86376 | <1% | 13 | $235.69 | |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 66 | $231.74 |
| 90662 | <1% | 132 | $224.88 | |
| 82379 | <1% | 12 | $210.20 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 25 | $209.85 |
| 82962 | <1% | 459 | $209.21 | |
| 82103 | <1% | 12 | $200.88 | |
| 91307 | <1% | 265 | $188.67 | |
| 86704 | <1% | 14 | $182.22 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 32 | $174.32 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 18 | $151.87 |
| 90480 | <1% | 12 | $145.47 | |
| 85380 | <1% | 14 | $123.76 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 14 | $109.21 |
| 82947 | <1% | 25 | $102.19 | |
| 82040 | <1% | 27 | $81.20 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $34.19 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 19 | $19.69 |
| 84295 | <1% | 35 | $13.33 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 621 | $9.89 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $8.09 |
| 91312 | <1% | 154 | $4.00 | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 14 | $2.08 |
| A6454 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 23 | $0.13 |
| A6456 | Zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 22 | $0.08 |
| 91301 | 0% | 95 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 47 | $0.00 |
| 91305 | 0% | 126 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 37 | $0.00 |
| 91303 | 0% | 12 | $0.00 | |
| 84132 | 0% | 12 | $0.00 | |
| 99152 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, JOHN (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Prestige Healthcare Resources INC. | Bladensburg, MD | $55.74M |
| Duke University Health System, INC. | Durham, NC | $11.62M |
| Proact Dental, INC. | Birmingham, AL | $9.47M |
| Duke University Health System, INC. | Durham, NC | $8.33M |
| Duke University Health System INC | Raleigh, NC | $7.84M |
| Duke University Health System, INC. | Durham, NC | $7.61M |
| Wishon Radiological Medical Group, INC. | Fresno, CA | $5.11M |
| Duke University Health System, INC. | Durham, NC | $5.01M |
| Duke University Health System, INC. | Raleigh, NC | $4.15M |
| Lighthouse Systems, LLC | Pharr, TX | $3.54M |
| Duke University Health System, INC. | Durham, NC | $1.59M |
| Old School LLC | Lakewood, OH | $800K |
| Gateway Medical Group LC | Okeechobee, FL | $447K |
| Triangle Geriatric and Memory Clinic, PLLC | Cary, NC | $437K |
| Duke University Health System, INC. | Durham, NC | $289K |
| Duke University Health System, INC. | Durham, NC | $118K |
| Associated Health Services, INC. | Durham, NC | $102K |
| Duke Health Integrated Practice, INC. | Durham, NC | $64K |
| Duke University Health System, INC. | Durham, NC | $49K |
| Women's Imaging Specialists in Healthcare | Fresno, CA | $36K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.